In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tyco Buys Bard, While Medtronic Scoops Up MiniMed

Executive Summary

Tyco's acquisition of CR Bard and Medtronic's purchase of MiniMed were announced almost simultaneously, but they hardly are true representations of ongoing consolidation in the medical device industry. Tyco bought Bard for manufacturing and distribution synergies, and Tyco officials talked about leveraging Bard as a growth platform in a slow-growth industry. Medtronic bought insulin pump maker MiniMed to expand into a significantly growing field in which it hasn't yet participated.

You may also be interested in...



Spun Out, Covidien Rolls On

Covidien, nearly a year removed from spinning out of scandal-plagued parent Tyco International, is pushing forward as an independent company. Covidien execs are investing in new product creation, sales and marketing efforts, and acquisitions. That means Covidien is about to make a big splash in the device industry, with devices bringing in two-thirds of this ambitious company's revenues.

Continuous Glucose Monitoring: A Revolution Powered by DexCom

Small company DexCom, finds itself a leader in continuous glucose monitoring, the hottest new segment of glucose monitoring, a business otherwise dominated by giant companies. Continuous glucose monitoring (CGM) is all the buzz at diabetes and critical care clinical meetings these days. CGM systems give diabetic patients in the home (or the hospital) glucose readings at any hour of the day without the need to get out the finger-stick testing paraphernalia. More than that, though, CGM is a new tool for achieving tight glycemic control, and avoiding the excursions above and below the normal glucose levels, which are responsible for the hospitalizations as well as the long-term harmful consequences of diabetes. As a frontrunner in the field, DexCom shares with Medtronic the challenge of proving the value of CGM to payers, especially since the task involves throwing over the gold standard by which successful glycemic control is measured-the HbA1c test.

Tyco Healthcare: Surviving Scandal

The (literally) trials and tribulations of its parent, Tyco International, have been both irrelevant to its strongly performing medical device business, Tyco Healthcare, and maddeningly distracting at the same time. But it has shaped the company's strategy, most notably in moving the company away from acquisitions as an engine of growth, forcing Tyco Healthcare to focus more on R&D and new product development.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel